시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 전이성 골질환 시장 보고서(2025년)
Metastatic Bone Disease Global Market Report 2025
상품코드 : 1825811
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,664,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,632,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,600,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

전이성 골질환 시장 규모는 향후 몇 년 동안 강력한 성장이 예상됩니다. 2029년에는 연평균 성장률(CAGR) 9.3%로 268억 2,000만 달러로 성장할 것입니다. 예측 기간의 성장은 노인 인구 증가, 신규 방사성의약품 개발에 대한 관심 증가, 급여 정책, 첨단 치료법 개발, 효과적인 통증 관리 치료에 대한 수요 증가, 전이성 골질환에 대한 인식 증가 등에 기인하는 것으로 보입니다. 예측 기간의 주요 동향으로는 진단 기술 개발, 진단 기술 향상, 치료 접근법의 신규성, 인공지능 및 머신러닝 알고리즘, 뼈 건강 관리 기술 개발 등을 꼽을 수 있습니다.

향후 5년간 9.3%의 성장률 전망은 지난번 전망치보다 0.6% 소폭 하락한 수치입니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향에 기인합니다. 관세 장벽은 네덜란드와 인도에서 공급되는 방사성의약품과 뼈 표적 치료제의 비용을 상승시키고, 완화치료의 선택권을 줄이며, 방사선 종양학 비용을 상승시킴으로써 미국의 종양학을 저해할 것으로 예상됩니다. 또한, 상호 관세와 무역 긴장과 제한의 증가로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향은 더욱 광범위하게 나타날 것으로 보입니다.

골암의 유병률 증가는 전이성 골질환 시장의 성장을 촉진할 것으로 예상됩니다. 골암은 뼈의 세포에서 발생하는 악성 종양으로 유전적 요인, 방사선 노출, 특정 화학제품에 대한 노출 등 환경적 요인에 의해 발생합니다. 골암은 원발성 종양의 암세포가 혈류와 림프계를 통해 퍼져 다른 뼈에 새로운 종양을 형성해 전이성 골질환으로 이어질 수 있습니다. 예를 들어, 미국에 본사를 둔 비영리 단체인 미국 암 협회는 2023년에 3,970건의 새로운 뼈 및 관절암 사례를 보고했는데, 이는 2022년에 보고된 3,910건보다 증가한 수치입니다. 따라서 골암의 유병률 증가가 전이성 골질환 시장의 성장을 주도하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 주요 기업과 혁신적 기업

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병

제34장 최근의 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

제36장 부록

KSM
영문 목차

영문목차

Metastatic bone disease refers to the condition where cancer cells spread from their original (primary) site to the bones, causing bone weakening and symptoms such as pain, fractures, spinal cord compression, and hypercalcemia. This indicates that the cancer has progressed and is more challenging to treat.

The main treatments for metastatic bone disease include medication, radiation therapy, surgical intervention, and tumor ablation therapy. Medication involves pharmaceutical drugs used to manage symptoms, slow disease progression, or address the underlying causes of bone metastases. These treatments are applicable to cancers originating from the breast, lung, thyroid, kidney, prostate, and other sites. The various end-users of these treatments include hospitals, specialty clinics, and ambulatory surgical centers.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The metastatic bone disease market research report is one of a series of new reports from The Business Research Company that provides metastatic bone disease market statistics, including the metastatic bone disease industry global market size, regional shares, competitors with metastatic bone disease market share, detailed metastatic bone disease market segments, market trends, and opportunities, and any further data you may need to thrive in the metastatic bone disease industry. These metastatic bone disease market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The metastatic bone disease market size has grown strongly in recent years. It will grow from $17.14 billion in 2024 to $18.82 billion in 2025 at a compound annual growth rate (CAGR) of 9.8%. The growth in the historic period can be attributed to an increased aging population, increased cancer awareness programs, growth in the demand for effective pain management therapies, high investment in drug discovery and development, and adoption of unhealthy lifestyles.

The metastatic bone disease market size is expected to see strong growth in the next few years. It will grow to $26.82 billion in 2029 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to the increasing geriatric population, increasing focus on developing novel radiopharmaceutical drugs, reimbursement policies, creation of cutting-edge treatment, growing demand for effective pain management therapies, and rising awareness about metastatic bone disease. Major trends in the forecast period include technological developments in diagnostics, improved diagnostic techniques, novelties in therapeutic approaches, artificial intelligence and machine learning algorithms, and technological developments in the management of bone health.

The forecast of 9.3% growth over the next five years reflects a modest reduction of 0.6% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper the U.S. oncology by increasing the cost of radiopharmaceuticals and bone-targeted agents sourced from the Netherlands and India, thereby reducing palliative care options and elevating radiation oncology costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing prevalence of bone cancer is expected to propel the growth of the metastatic bone disease market. Bone cancer, a malignant tumor originating in the cells of the bone, is driven by genetic factors, radiation exposure, and environmental factors such as exposure to certain chemicals. Bone cancer can lead to metastatic bone disease as cancer cells from the primary tumor spread through the bloodstream or lymphatic system, forming new tumors in other bones. For instance, in 2023, the American Cancer Society, a US-based non-profit organization, reported 3,970 new cases of bone and joint cancer, an increase from the 3,910 cases reported in 2022. Therefore, the increasing prevalence of bone cancer is driving the growth of the metastatic bone disease market.

Major companies in the metastatic bone disease market are developing targeted therapies to improve treatment outcomes. These targeted therapies help in metastatic bone disease by precisely targeting cancer cells, minimizing damage to healthy cells, and offering a personalized treatment approach based on the individual patient's molecular characteristics. For example, in March 2022, Novartis AG, a Switzerland-based pharmaceutical company, introduced Zometa (zoledronic acid), a bisphosphonate medication approved for the prevention of skeletal-related events in patients with bone metastases from solid tumors and multiple myeloma. These advancements aim to improve treatment outcomes and quality of life for patients with metastatic bone disease.

In May 2024, Telix Pharmaceuticals Limited, an Australia-based biopharmaceutical company, acquired QSAM Biosciences for an undisclosed amount. This acquisition aims to bolster Telix's therapeutic pipeline, strengthening its position in radiopharmaceutical innovation and widening its focus on oncology and rare diseases. Through this deal, Telix intends to accelerate the development and delivery of treatments for bone metastases, aiming to provide significant benefits to affected patients. QSAM Biosciences Inc. is a US-based company developing therapeutic radiopharmaceuticals for primary and metastatic bone cancer.

Major companies operating in the metastatic bone disease market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Takeda Pharmaceutical Company Limited, Medtronic plc, Eli Lilly and Company, Amgen Inc., Boston Scientific Corporation, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Jazz Pharmaceuticals Inc., Exelixis Inc., BeiGene Ltd., Mylan N.V., Novocure GmbH, Galapagos NV, Telix Pharmaceuticals Limited

North America was the largest region in the metastatic bone disease market in 2024. The regions covered in the metastatic bone disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the metastatic bone disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The metastatic bone disease market consists of revenues earned by entities by providing services such as chemotherapy, hormone therapy, bisphosphonates, opiate therapy, and immunotherapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The metastatic bone disease market includes sales of intramedullary rods, plates and screws, prosthetic devices, spinal instrumentation, and radiation therapy accessories. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Metastatic Bone Disease Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on metastatic bone disease market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for metastatic bone disease ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The metastatic bone disease market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Metastatic Bone Disease Market Characteristics

3. Metastatic Bone Disease Market Trends And Strategies

4. Metastatic Bone Disease Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Metastatic Bone Disease Growth Analysis And Strategic Analysis Framework

6. Metastatic Bone Disease Market Segmentation

7. Metastatic Bone Disease Market Regional And Country Analysis

8. Asia-Pacific Metastatic Bone Disease Market

9. China Metastatic Bone Disease Market

10. India Metastatic Bone Disease Market

11. Japan Metastatic Bone Disease Market

12. Australia Metastatic Bone Disease Market

13. Indonesia Metastatic Bone Disease Market

14. South Korea Metastatic Bone Disease Market

15. Western Europe Metastatic Bone Disease Market

16. UK Metastatic Bone Disease Market

17. Germany Metastatic Bone Disease Market

18. France Metastatic Bone Disease Market

19. Italy Metastatic Bone Disease Market

20. Spain Metastatic Bone Disease Market

21. Eastern Europe Metastatic Bone Disease Market

22. Russia Metastatic Bone Disease Market

23. North America Metastatic Bone Disease Market

24. USA Metastatic Bone Disease Market

25. Canada Metastatic Bone Disease Market

26. South America Metastatic Bone Disease Market

27. Brazil Metastatic Bone Disease Market

28. Middle East Metastatic Bone Disease Market

29. Africa Metastatic Bone Disease Market

30. Metastatic Bone Disease Market Competitive Landscape And Company Profiles

31. Metastatic Bone Disease Market Other Major And Innovative Companies

32. Global Metastatic Bone Disease Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Metastatic Bone Disease Market

34. Recent Developments In The Metastatic Bone Disease Market

35. Metastatic Bone Disease Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기